Back to Peptides

BPC-157

Healing & Regeneration

BPC-157 is a synthetic peptide derived from a sequence found in human gastric juice. It has been extensively studied in rodent models for its effects on healing, angiogenesis, and inflammation reduction. Though widely researched, it is not approved for human or veterinary use.

Reconstitute
3 mL BAC + 10mg vial
33 mcg/unit
Daily Range
0.25–1 mg Subcutaneous (SQ)
2x daily
Standard Dose
0.5 mg
Cycle
4–8 weeks
then reassess
BPC-157peptidetissue repairanti-inflammatory

Dosing & Reconstitution Guide

In rodent studies, BPC-157 has been administered via intraperitoneal injection or oral routes, typically in the 10–20 μg/kg range. No standardized dosing exists for human application, and this compound is not approved by the FDA. All dosing references are based on animal models and for informational purposes only.

Standard / Gradual Approach

10mg Vialstandard
PhaseDoseVolume
Week 1250mcg7 units
Week 2250mcg7 units
Week 3500mcg15 units
Week 4500mcg15 units

Protocol Summary

Subcutaneous (SQ): 2x daily · Dose range 0.25–1 mg with gradual titration
Oral: daily · Dose range 0.5–2 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

Daily injections for 4–6 weeks, then reassess healing response.

🧪 Quick Start

Vial Size
10 mg
BAC Water
3 mL
Concentration
3300 mcg/unit
Starting Dose
250 mcg
Maintenance Dose
500 mcg twice daily

Potential Benefits & Use Cases

BPC-157 is for laboratory research only. It is not approved for human or veterinary use.
Supports tissue repair in gut, tendon, muscle, and skin injury models (strong preclinical)
Demonstrates anti-inflammatory and cytoprotective properties across multiple tissue types (strong preclinical)
Shows good tolerability with no serious adverse events in Phase I IV safety study (Phase 1)
Small observational study: 7/12 chronic knee pain patients experienced relief >6 months (limited human data)
Clinical data Strong preclinical Limited data

Mechanism of Action

→Promotes angiogenesis
→Enhances nitric oxide production
→Upregulates VEGF signaling
→Increases GH receptor expression in tendon fibroblasts
→Stabilizes microvascular endothelium
→Accelerates fibroblast migration and F-actin formation
→Reduces oxidative stress and pro-inflammatory cytokines

Stacking Synergies

+
TB-500
Enhanced connective tissue repair & muscle recovery
+
KPV
Anti-inflammatory gut healing synergy

Lifestyle & Optimization

diet

High-quality protein intake (1.2g per pound body weight). Adequate micronutrients.

sleep

Consistent sleep of 8+ hours nightly. Stay well-hydrated to support tissue repair.

timing

Inject near injury site 1–2x daily. Can also be taken orally for gut issues.

exercise

Allow adequate recovery time between intense workouts (at least 1 rest day per week).

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
Journal of Pharmacological Sciences — BPC-157 promotes fistula healingReference
Pharmaceuticals (MDPI) — Józwiak M et al. BPC-157 reviewReference
Current Pharmaceutical Design — Sikiric P et al. BPC-157Reference
Life Sciences — Seiwerth S et al. BPC-157 and growth factorsReference
HSS Journal — Vasireddi N et al. BPC-157 in orthopedic sports medicineReference
Journal of Orthopaedic Research — Chang CH et al. BPC-157 tendon-to-boneReference
ClinicalTrials.gov — NCT02637284: PCO-02 Phase IReference
World Journal of Gastroenterology — Sikiric P et al.Reference

Side Effects & Safety

Common Side Effects

• Anxiety and panic attacks (frequently user-reported)
• Nausea, fatigue, loss of appetite (user-reported)
• Insomnia and sleep disturbances (user-reported)
• Heart palpitations (user-reported)

Contraindications & Warnings

• Depression and anhedonia (user-reported)
• Contamination risk: 30% of online peptides contain incorrect sequences; 65% exceed endotoxin thresholds (quality study)

🧮 Dose Calculator

Concentration
33.3
mcg/unit
Draw Volume
15
units (0.150 mL)
For a 500 mcg dose, draw 15 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
Provides direct tissue delivery possibly enhancing repair mechanisms.
Oral Administration
Effective for local gastrointestinal healing. Systemic absorption is likely limited based on animal data.
Half-Life
Estimated ~4 hours (based on animal data; no human PK studies published).
Degradation
Predominantly metabolized in the liver and intestines.
Tissue Specificity
Demonstrated efficacy in gastric tissues and musculoskeletal system.
⚗️

Peptide Details

Molecular Weight
1419.53552
Formula
C62H98N16O22
Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
⚖️

Legal Status & Regulatory

RegionStatus
EUNot Approved
FDANot Approved
CanadaNot Approved
AustraliaNot Approved

Storage Instructions

Lyophilized (Powder)
Store lyophilized powder at 2-8°C. Reconstituted solution remains stable at 2-8°C for up to 28 days. For oral use, dissolve in distilled water or saline solution just before administration.
Reconstituted (Mixed)
Refrigerate at 2–8°C after reconstitution. Use within 28 days.